These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 16445813)

  • 1. Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience.
    Dolan G
    Haemophilia; 2006 Mar; 12 Suppl 1():16-20; discussion 26-8. PubMed ID: 16445813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products and their impact on patients with inherited bleeding disorders.
    Millar CM; Connor N; Dolan G; Lee CA; Makris M; Wilde J; Winter M; Ironside JW; Gill N; Hill FG
    Haemophilia; 2010 Mar; 16(2):305-15. PubMed ID: 20487442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of variant Creutzfeldt-Jakob disease among UK patients with bleeding disorders, known to have received potentially contaminated plasma products.
    Zaman SM; Hill FG; Palmer B; Millar CM; Bone A; Molesworth AM; Connor N; Lee CA; Dolan G; Wilde JT; Gill ON; Makris M
    Haemophilia; 2011 Nov; 17(6):931-7. PubMed ID: 21342369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variant Creutzfeldt-Jakob disease: risk of transmission by blood transfusion and blood therapies.
    Ironside JW
    Haemophilia; 2006 Mar; 12 Suppl 1():8-15; discussion 26-8. PubMed ID: 16445812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study.
    Hewitt PE; Llewelyn CA; Mackenzie J; Will RG
    Vox Sang; 2006 Oct; 91(3):221-30. PubMed ID: 16958834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of variant Creuzfeldt-Jakob disease from factor concentrates: current perspectives.
    Farrugia A
    Haemophilia; 2002 May; 8(3):230-5. PubMed ID: 12010416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Creutzfeldt-Jakob disease and haemophilia: assessment of risk.
    Evatt B
    Haemophilia; 2000 Jul; 6 Suppl 1():94-9. PubMed ID: 10982274
    [No Abstract]   [Full Text] [Related]  

  • 8. Insights into the management of emerging infections: regulating variant Creutzfeldt-Jakob disease transfusion risk in the UK and the US.
    Ponte ML
    PLoS Med; 2006 Oct; 3(10):e342. PubMed ID: 17076547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variant Creutzfeldt-Jakob disease and exposure to fractionated plasma products.
    Ward HJ; MacKenzie JM; Llewelyn CA; Knight RS; Hewitt PE; Connor N; Molesworth A; Will RG
    Vox Sang; 2009 Oct; 97(3):207-10. PubMed ID: 19538514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attributable testing for abnormal prion protein, database linkage, and blood-borne vCJD risks.
    Bird SM
    Lancet; 2004 Oct 9-15; 364(9442):1362-4. PubMed ID: 15474140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee of the UKHCDO. United Kingdom Haemophilia Centre Directors' Organisation.
    Ludlam CA
    Lancet; 1997 Dec; 350(9092):1704. PubMed ID: 9400534
    [No Abstract]   [Full Text] [Related]  

  • 12. Batch recall of French plasma-derived products due to variant Creutzfeldt-Jakob disease risk: the psychological impact on haemophilic patients, changes in their therapeutic demands and behaviour and ethical considerations.
    Aouba A; Harroche A; Frenzel L; Torchet MF; Rothschild C; François I; Mamzer-Bruneel MF
    Haemophilia; 2015 Jan; 21(1):27-33. PubMed ID: 25545300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
    Turner ML; Ludlam CA
    Br J Haematol; 2009 Jan; 144(1):14-23. PubMed ID: 18950452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Theoretical risk of vCJD transmission via blood transfusion. Leukocyte and erythrocyte depletion of the transfusion blood is a practice in many countries].
    Andersen O
    Lakartidningen; 2002 Mar; 99(12):1310-4. PubMed ID: 11998162
    [No Abstract]   [Full Text] [Related]  

  • 15. Variant Creutzfeldt-Jakob disease (vCJD). Precautionary measures against the risk of transmission of the agent of vCJD by blood transfusion.
    Wkly Epidemiol Rec; 2000 Nov; 75(47):377-9. PubMed ID: 11144617
    [No Abstract]   [Full Text] [Related]  

  • 16. Dealing with the uncertain risk of variant Creutzfeldt-Jakob disease transmission by coagulation replacement products.
    Millar CM; Makris M
    Br J Haematol; 2012 Aug; 158(4):442-52. PubMed ID: 22775486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variant Creutzfeldt-Jakob disease in a transfusion recipient: coincidence or cause?
    Chohan G; Llewelyn C; Mackenzie J; Cousens S; Kennedy A; Will R; Hewitt P
    Transfusion; 2010 May; 50(5):1003-6. PubMed ID: 20230536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dental treatment of a patient in the new 'at-risk' category for CJD.
    Hamilton K; Brewer A; Smith A
    J Hosp Infect; 2004 Jun; 57(2):184-5. PubMed ID: 15183253
    [No Abstract]   [Full Text] [Related]  

  • 19. UK accused over risk of CJD in plasma...and latest BSE beef ban 'comes too late'.
    Butler D
    Nature; 1997 Dec; 390(6660):541. PubMed ID: 9403673
    [No Abstract]   [Full Text] [Related]  

  • 20. vCJD and blood transfusion in the United Kingdom.
    Hewitt P
    Transfus Clin Biol; 2006 Nov; 13(5):312-6. PubMed ID: 17188541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.